1.DeVita VJ, Lawrence T, Rosenberg S. Cancer: Principles and Practice of Oncology. 9th ed. ed. Philadelphia, Pa; 2011. 2.Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008;113:1953-68. 3.Mendoza A, Cabalé M, Fernández ME, Selva JC. Resumen Incidencia de tumores Cerebrales primarios en adultos. In: V Congreso Virtual Hispanoamericano de Anatomía Patológica; 2004. 4.Meyer MA. Malignant gliomas in adults. N Engl J Med 2008;359:1850; author reply 5.Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507. 6.Stupp R, Tonn JC, Brada M, Pentheroudakis G. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v190-3. 7.Lorenzoni J, Torrico A, Villanueva P, Gederlini A, Torrealba G. Surgery for high-grade gliomas in a developing country: survival estimation using a simple stratification system. Surg Neurol 2008;70:591-7; discussion 7. 8.Oszvald A, Guresir E, Setzer M, et al. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 2012;116:357-64. 9.Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002;64:259-73. 10.Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. 11.Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66. 12.Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 2007;11:iii-iv, ix-221. 13.Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Temozolomide for high grade glioma. Cochrane Database Syst Rev 2008:CD007415. 14.Koshy M, Villano JL, Dolecek TA, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 2012;107:207-12. 15.Roesler R, Brunetto AT, Abujamra AL, de Farias CB, Brunetto AL, Schwartsmann G. Current and emerging molecular targets in glioma. Expert Rev Anticancer Ther 2010;10:1735-51. 16.Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. BMC Cancer 2011;11:325. 17.Fuentes-Raspall R, Vilardell L, Perez-Bueno F, et al. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005. J Neurooncol 2011;101:117-23. 18.Johnson DR, Ma DJ, Buckner JC, Hammack JE. Conditional probability of long-term survival in glioblastoma: A population-based analysis. Cancer 2012. 19.Gorlia T, Stupp R, Brandes AA, et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 2012;48:1176-84. 20.Donato V, Papaleo A, Castrichino A, et al. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori 2007;93:248-56. 21.Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006;24:2563-9. 22.Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J Neurooncol 2011;105:325-35. 23.Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9. 24.Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40. 25.Ramos TC, Figueredo J, Catala M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006;5:375-9. 26.Crombet T. Use the humanized anti-EGFR MAb (nimotuzumab) and radiotherapy for the treatment of high grade glioma patients European Journal of Cancer, suppl 2008 6:168. 27.Crombet T, Cabanas R, Alert J, et al. Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: preliminary results from a phase II study Eur J Cancer Suppl 2009;7 28.Lam C, Bouffet E, Bartels U. Nimotuzumab in pediatric glioma. Future Oncol 2009;5:1349-61. 29.MacDonald TJ, Aguilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents. Neuro Oncol 2011;13:1049-58. 30.Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 2011;11:247-56. 31.Mateos ME, Lopez-Laso E, Izquierdo L, Perez-Navero JL, Garcia S, Garzas C. Response to nimotuzumab in a child with a progressive diffuse intrinsic pontine glioma. Pediatr Int 2011;53:261-3. 32.Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14:1131-8. 33. Nimotuzumab drug marketed approval 2011. (Accessed 19/02/02, 2002, at http://www.cecmed.sld.cu/Pages/RegSan.htm.) 34.Yabroff KR, Harlan L, Zeruto C, Abrams J, Mann B. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. Neuro Oncol 2012;14:351-9. 35.Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85. 36.Ye F, Gao Q, Cai MJ. Therapeutic targeting of EGFR in malignant gliomas. Expert Opin Ther Targets 2010;14:303-16. 37.Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304. 38.Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997;3:71-81. 39.Arteaga ME, Ledon N, Casaco A, et al. Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab. Cancer Biol Ther 2007;6:1390-5. 40.Arteaga-Perez ME, Maceira M, Casaco A, et al. Multiple dose toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 intravenously administered to Cercopithecus aethiops sabaeus monkeys. Hum Exp Toxicol 2004;23:219-27. 41.Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003;39 Suppl C:1-16. 42.Shimodaira H, Komine K, Soeda H, Ishioka C. [Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody]. Gan To Kagaku Ryoho 2010;37:795-8. 43.Soeda H, Shimodaira H, Ishioka C. [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer]. Gan To Kagaku Ryoho 2011;38:1079-83. 44.Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003;532:253-68. 45.Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54. 46.Verduzco-Rodriguez L, Aguirre-Gonzalez EH, Verduzco-Aguirre HC. Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma. Hematol Oncol Stem Cell Ther 2011;4:182-4. 47.Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, Nair P. Nimotuzumab with chemoradiation confers survival advantage in treatment naive head and neck tumors overexpressing EGFR. Cancer Biol Ther 2010;10. 48.Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009;1:41-8. 49.Crombet T, Torres O, Rodriguez V, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 2001;20:131-6. 50.F. Bach, Westphal M. Current status of a phase III trial of nimotuzumab (ti-EGF-R) in newly diagnosed glioblastoma. J Clin Oncol 2011;29. 51.Fleischhack G, Siegler S, Warmuth-Metz M, et al. Final results of a phase III study consisting of nimotuzumab and concomitant standard radiotherapy for the treatment of newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer 2009;Suppl.:755. 52.Yang QY, Shen D, Sai K, et al. [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. Zhonghua Zhong Liu Za Zhi 2011;33:232-5. 53.Ling Y, Chen J, Tao M, Chu X, Zhang X. A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma. J Thorac Dis 2012;4:58-62. 54.Zhao KL, Hu XC, Wu XH, Fu XL, Fan M, Jiang GL. A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus. Invest New Drugs 2011. 55.Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 2012;13:600-5. 56.Strumberg D, Schultheis B, Scheulen ME, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2010. 57.Macias A, Neninger E, Santiesteban E, et al. Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases. Eur J Cancer 2008;Suppl:160-1. 58.Solomon MT, Selva JC, Figueredo J, et al. Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients. J Clin Oncol 2012;30. 59.Piedra P, Morejón O. Report of the Fifth Nimotuzumab Global Meeting. Biotecnología Aplicada 2010;27:56-61. 60.Saurez G. Reporte del Séptimo encuentro científico internacional: Nimo–meeting 2012 en la sesión de tumores cerebrales. . Rev Cubana Neurol Neurocir 2012;2:5 61.Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. 62.Inc. SI. SAS OnlineDoc Version 9.1.3. . In. 9.1.3 ed. Cary, NC, USA. ; 2004.